It was tried on 2 patients with diffuse SSc and based on success then expanded to a phase 2/3 trial ( 31 - 35 ), which showed a trend toward skin and lung improvement in 87 patients ( 5 ).
1
—
—
It was tried on 2 patients with diffuse SSc and based on success then expanded to a phase 2/3 trial ( 31 - 35 ), which showed a trend toward skin and lung improvement in 87 patients ( 5 ).